Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q1- Text added to 2023 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
absence, aim, allocation, baseline, behavioral, breakthrough, bunionectomy, composite, composition, dose, dosed, electrophysiological, fat, feasible, fluctuation, Genetic, genetically, human, hydromorphone, intrinsic, lower, month, morphine, MRI, multicenter, muscle, mutant, pharmacodynamic, pharmacological, placebo, post, protein, randomize, randomized, randomly, rate, RSA, RSU, seizure, shown, skeletal, Strasbourg, suppression, SynapCell, theoretical, tolerability, vivo
Valuein 2023 Q1 filing- Value in 2023 Q2 filing
Original filings
Filing view